Related Experiment Video
Updated: Feb 6, 2026
09:52
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma
Published on: January 25, 2015
13.9K
Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment?
Deepti Chopra1, Bharti Bhandari1
1Department of Pharmacology and Physiology, Government Institute of Medical Sciences, Greater Noida, U.P, India.
Infectious Disorders Drug Targets
|August 17, 2018
Summary
Sofosbuvir, a potent nucleoside inhibitor, offers a new dimension in treating chronic hepatitis C (HCV). This drug demonstrates high efficacy across all HCV genotypes with a favorable safety profile, transforming patient care.
Area of Science:
- Hepatology
- Virology
- Pharmacology
Background:
- Chronic hepatitis C (HCV) affects over 1% of the global population, posing a significant public health challenge.
- Treatment has evolved from Interferon-based therapies to Direct-Acting Antivirals (DAAs), offering new hope for patients ineligible for older treatments.
Purpose of the Study:
- This review focuses on Sofosbuvir, a key Direct-Acting Antiviral (DAA) and nucleoside inhibitor.
- To evaluate Sofosbuvir's potency, resistance profile, activity against all HCV genotypes, and safety.
Main Methods:
- Review of clinical trial data (PROTON, ELECTRON, FUSION, POSITRON) and chemical properties of Sofosbuvir.
- Analysis of Sofosbuvir as a phosphoramidate prodrug and its mechanism as an HCV NS5B polymerase inhibitor.
Main Results:
- Sofosbuvir is a highly potent inhibitor of HCV NS5B polymerase.
- Demonstrates efficacy against all genotypes of HCV with a good safety profile and few mild to moderate adverse effects.
- FDA approved in 2013, it has shown substantial impact in clinical trials.
Conclusions:
- Sofosbuvir represents a significant advancement in chronic HCV treatment.
- Its efficacy, broad-genotype activity, and favorable safety profile make it a crucial therapeutic option.
Related Concept Videos
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
281
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
01:21Hepatic Portal System
6.0K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
247
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
247
01:16Hepatic Drug Excretion: Influencing Factors
592
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
592
01:14Hepatic Drug Clearance: Role of Transporters
310
In the liver and bile canaliculi, influx and efflux transporters modification can influence intrinsic clearance. Transporters play a significant role in moving drugs within liver cells. Elaborate models, such as the Biopharmaceutical Classification System (BCS), are essential to relate transporters to drug disposition. This system categorizes drugs into four classes based on solubility and permeability, providing insights into elimination routes and the effects of transporters following oral...
310
01:17Hepatic Drug Excretion: Enterohepatic Cycling
2.8K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
2.8K